302 related articles for article (PubMed ID: 30138668)
1. Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma.
Corren J; Castro M; Chanez P; Fabbri L; Joish VN; Amin N; Graham NMH; Mastey V; Abbé A; Taniou C; Mahajan P; Teper A; Pirozzi G; Eckert L
Ann Allergy Asthma Immunol; 2019 Jan; 122(1):41-49.e2. PubMed ID: 30138668
[TBL] [Abstract][Full Text] [Related]
2. Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline.
Bourdin A; Papi AA; Corren J; Virchow JC; Rice MS; Deniz Y; Djandji M; Rowe P; Pavord ID
Allergy; 2021 Jan; 76(1):269-280. PubMed ID: 33010038
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study.
Wechsler ME; Ford LB; Maspero JF; Pavord ID; Papi A; Bourdin A; Watz H; Castro M; Nenasheva NM; Tohda Y; Langton D; Cardona G; Domingo C; Park HS; Chapman KR; Mao X; Zhang Y; Khan AH; Deniz Y; Rowe PJ; Kapoor U; Khokhar FA; Mannent LP; Ruddy M; Laws E; Amin N; Hardin M
Lancet Respir Med; 2022 Jan; 10(1):11-25. PubMed ID: 34597534
[TBL] [Abstract][Full Text] [Related]
4. Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma.
Laidlaw TM; Bachert C; Amin N; Desrosiers M; Hellings PW; Mullol J; Maspero JF; Gevaert P; Zhang M; Mao X; Khan AH; Kamat S; Patel N; Graham NMH; Ruddy M; Staudinger H; Mannent LP
Ann Allergy Asthma Immunol; 2021 May; 126(5):584-592.e1. PubMed ID: 33465455
[TBL] [Abstract][Full Text] [Related]
5. Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study.
Tohda Y; Nakamura Y; Fujisawa T; Ebisawa M; Arima K; Miyata M; Takahashi Y; Rice MS; Deniz Y; Rowe P; Patel N; Graham NMH; Teper A
Allergol Int; 2020 Oct; 69(4):578-587. PubMed ID: 32444306
[TBL] [Abstract][Full Text] [Related]
6. Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baseline.
Bourdin A; Virchow JC; Papi A; Lugogo NL; Bardin P; Antila M; Halpin DMG; Daizadeh N; Djandji M; Ortiz B; Jacob-Nara JA; Gall R; Deniz Y; Rowe PJ
Respir Med; 2022 Oct; 202():106938. PubMed ID: 36087550
[TBL] [Abstract][Full Text] [Related]
7. Dupilumab: A Review in Moderate to Severe Asthma.
Deeks ED
Drugs; 2019 Nov; 79(17):1885-1895. PubMed ID: 31728838
[TBL] [Abstract][Full Text] [Related]
8. Dupilumab efficacy in high sleep disturbance management among patients with type 2 asthma.
Maspero JF; Shafazand S; Cole J; Pavord ID; Busse WW; Msihid J; Gall R; Soler X; Radwan A; Khan AH; de Prado Gómez L; Jacob-Nara JA
Respir Med; 2023 Nov; 218():107344. PubMed ID: 37659435
[TBL] [Abstract][Full Text] [Related]
9. Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma.
Corren J; Katelaris CH; Castro M; Maspero JF; Ford LB; Halpin DMG; Rice MS; Radwan A; Deniz Y; Rowe PJ; Teper A; Djandji M
Eur Respir J; 2021 Oct; 58(4):. PubMed ID: 34266940
[TBL] [Abstract][Full Text] [Related]
10. Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY.
Corren J; Garcia Gil E; Griffiths JM; Parnes JR; van der Merwe R; Sałapa K; O'Quinn S
Ann Allergy Asthma Immunol; 2021 Feb; 126(2):187-193. PubMed ID: 33169672
[TBL] [Abstract][Full Text] [Related]
11. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
[TBL] [Abstract][Full Text] [Related]
12. Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study.
Fiocchi AG; Phipatanakul W; Zeiger RS; Durrani SR; Cole J; Msihid J; Gall R; Jacob-Nara JA; Deniz Y; Rowe PJ; Lederer DJ; Hardin M; Zhang Y; Khan AH
Eur Respir J; 2023 Nov; 62(5):. PubMed ID: 37734856
[TBL] [Abstract][Full Text] [Related]
13. Dupilumab efficacy and safety in Latin American patients with uncontrolled, moderate-to-severe asthma: phase 3 LIBERTY ASTHMA QUEST study.
Maspero JF; Cardona G; Schonffeldt P; Tolcachier A; González-Diaz SN; Yañez A; Galvao CE; Msihid J; Gall R; Siddiqui S; Rowe PJ; Deniz Y; Jacob-Nara JA; Djandji M
J Asthma; 2023 May; 60(5):981-990. PubMed ID: 36066123
[TBL] [Abstract][Full Text] [Related]
14. Dupilumab Efficacy in Patients With Uncontrolled or Oral Corticosteroid-Dependent Allergic and Nonallergic Asthma.
Brusselle G; Quirce S; Papi A; Kuna P; Chipps BE; Hanania NA; Blaiss M; Msihid J; Jacob-Nara JA; Deniz Y; Rowe PJ; Gall R; Ortiz B; Djandji M; Radwan A
J Allergy Clin Immunol Pract; 2023 Mar; 11(3):873-884.e11. PubMed ID: 36572184
[TBL] [Abstract][Full Text] [Related]
15. Impact of dupilumab across seasons in patients with type 2, uncontrolled, moderate-to-severe asthma.
Peters AT; Sagara H; Corren J; Domingo C; Altincatal A; Soler X; Pandit-Abid N; Crikelair N; Rowe PJ; Jacob-Nara JA; Deniz Y
Ann Allergy Asthma Immunol; 2024 Apr; 132(4):477-484.e4. PubMed ID: 38013139
[TBL] [Abstract][Full Text] [Related]
16. Dupilumab long-term efficacy in patients with non-OCS-dependent asthma with and without evidence of allergic asthma.
Sher LD; Corren J; Pavord ID; Daizadeh N; Altincatal A; Soler X; Djandji M; Radwan A; Jacob-Nara JA; Deniz Y; Rowe PJ
J Asthma; 2023 Sep; 60(9):1767-1774. PubMed ID: 36876957
[TBL] [Abstract][Full Text] [Related]
17. Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of inhaled corticosteroids dose.
Pavord ID; Bourdin A; Papi A; Domingo C; Corren J; Altincatal A; Radwan A; Pandit-Abid N; Jacob-Nara JA; Deniz Y; Rowe PJ; Laws E; Lederer DJ; Hardin M
Allergy; 2023 Nov; 78(11):2921-2932. PubMed ID: 37431558
[TBL] [Abstract][Full Text] [Related]
18. The long-term effect of dupilumab on dyspnea, sleep, and activity in oral corticosteroid-dependent severe asthma.
Sher LD; Passalacqua G; Taillé C; Cohn L; Daizadeh N; Pandit-Abid N; Soler X; Khodzhayev A; Jacob-Nara JA; Deniz Y; Rowe PJ; Nag A; Zhang Y
Ann Allergy Asthma Immunol; 2023 Mar; 130(3):298-304. PubMed ID: 36509407
[TBL] [Abstract][Full Text] [Related]
19. Dupilumab improves long-term outcomes in patients with uncontrolled, moderate-to-severe GINA-based type 2 asthma, irrespective of allergic status.
Rabe KF; Pavord ID; Busse WW; Chupp GL; Izuhara K; Altincatal A; Gall R; Pandit-Abid N; Deniz Y; Rowe PJ; Jacob-Nara JA; Radwan A
Allergy; 2023 Aug; 78(8):2148-2156. PubMed ID: 37073882
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy of dupilumab in asthma with or without chronic rhinosinusitis and nasal polyps.
Berger P; Menzies-Gow A; Peters AT; Kuna P; Rabe KF; Altincatal A; Soler X; Pandit-Abid N; Siddiqui S; Jacob-Nara JA; Deniz Y; Rowe PJ
Ann Allergy Asthma Immunol; 2023 Feb; 130(2):215-224. PubMed ID: 36356712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
